Astex Pharmaceuticals to Present at NewsMakers in the Biotech Industry on October 21st

DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery, development and commercialization of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, will present at the 18th Annual NewsMakers in the Biotech Industry conference on Friday, October 21st in New York.

The Company's presentation will begin at 10:00 a.m. ET. A live webcast of the presentation will be available in the Investor Events section of the Company's website, www.astx.com. The webcast will be archived for 30 days.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. The Company is developing a proprietary pipeline of novel cancer therapeutics, will selectively in-license assets possessing a strategic fit with an attractive cost – value ratio, and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals, formerly SuperGen, developed Dacogen® and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.



CONTACT:

Astex Pharmaceuticals, Inc.
Corporate Communications & Marketing:
Timothy L. Enns, 925-560-2810
Senior Vice President
[email protected]
Investor Relations:
Susanna Chau, 925-560-2845
Manager
[email protected]
or
The Trout Group
Alan Roemer, 646-378-2945
Managing Director
[email protected]
or
College Hill
Melanie Toyne-Sewell (Europe), +44 20 7866 7866
Rebecca Skye Dietrich (US), 857-241-0795
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.